Life AI Net
Home
Archive
Calculators
Directory
Newsletter
Login
English
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Home
Archive
Calculators
Directory
Newsletter
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Login
Home
Archive
Calculators
Directory
More
Live
Cell
mRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity
Clinical OMICs
Beyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics
BioPharma Dive
Stealthy startup Treeline plans a reverse merger
10x Genomics Blog
10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz
Endpoints News
How K Health moved AI chatbots into hospitals
10x Genomics News
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpace
Endpoints News
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
Endpoints News
Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
FierceBiotech
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program
FierceBiotech
Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal
FierceBiotech
Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M
Endpoints News
Endpoints Women in Biopharma: Nominate for 2026
Cell
mRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity
Clinical OMICs
Beyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics
BioPharma Dive
Stealthy startup Treeline plans a reverse merger
10x Genomics Blog
10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz
Endpoints News
How K Health moved AI chatbots into hospitals
10x Genomics News
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpace
Endpoints News
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
Endpoints News
Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
FierceBiotech
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program
FierceBiotech
Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal
FierceBiotech
Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M
Endpoints News
Endpoints Women in Biopharma: Nominate for 2026
Archive
This story is not available in the archive.